# Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer

> **NCT00154882** · PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel (Phyxol) , Cisplatin

## Key facts

- **NCT ID:** NCT00154882
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2003-09
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2010-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154882, "Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00154882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*